StockTipsArenaBeta

BUY Lupin Limited — Somil Mehta, Sharekhan

BUYLupin Limited

bySomil Mehta, SharekhanHorizon: 1–3 months18 Jun 2026via CNBC Awaaz.

Entry₹2,326.9Inferred
Target₹2,430
Total upside +4.43% (call closed)
Stop loss₹2,270-2.45% risk
Exit₹2,43030 Jun 2026, 12:06 pm
Target hit+4.43%0.00%upside left
Follow Somil Mehta for new calls(38% target hit, 42 closed calls)Get alertsWatch LUPIN for new buy/sell callsGet alertsSee 1 active Short-term call on LUPINSee 10 active Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Sept, 7:00 pm IST
11 supporting0 opposing
Supports the BUY call (11)

Lupin Limited received tentative approval from the U.S. FDA for Enzalutamide Tablets on June 26, 2026. This is a step towards potential market approval.

NSE · Press Release·26 Jun · 4d ago

(opens in new tab)

4 advisors have active long-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·19 Jun · 1w ago

Lupin Ltd has launched Azilsartan Medoxomil Tablets in the United States market.

BSE · Company Update·17 Jun · 2w ago

(opens in new tab)

Lupin Ltd is collaborating with ERN to launch Luforbec (beclometasone/formoterol) pMDI in Spain.

BSE · Company Update·8 Jun · 3w ago

(opens in new tab)

Lupin received approval from the U.S. FDA for Ranluspec (Ranibizumab) Injection.

BSE · Company Update·4 Jun · 4w ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.